Molecular Mechanisms of Mucormycosis Pathogenesis: Host–Pathogen Interactions and Immune Evasion
Open Access
Abstract
Mucormycosis, triggered by fungi of the order Mucorales, represents a potentially fatal invasive mycosis, with death rates over 50% despite intensive therapy. The COVID-19 pandemic brought a sharp increase in cases, especially in individuals with diabetes mellitus and those undergoing immunosuppressive treatment, emphasizing significant gaps in our comprehension of disease pathogenesis. Emerging molecular studies have highlighted key virulence factors, such as the CotH family of invasins that facilitate endothelial invasion via interaction with glucose-regulated protein 78 (GRP78), complex iron acquisition systems necessary for fungal growth, and the release of mucoricin, a ricin-like toxin that impairs vascular integrity. Host defense depends mainly on innate immunity, with neutrophils and macrophages working as critical effector cells, while adaptive Th1 and Th17 responses aid in the fungal removal. Mucorales use a variety of immune evasion techniques, such as pathogen-associated molecular pattern (PAMP) masking via cell wall transformations, resistance to phagocytic death, and metabolic utilization of host factors including hyperglycemia and increased free iron in diabetic ketoacidosis (DKA). This review summarizes current evidence of the molecular processes underlying mucormycosis pathogenesis, underscoring host–pathogen interactions at the cellular and molecular levels, immune evasion tactics, and translational potential for new diagnostic and therapeutic approaches. Comprehending these molecular processes is crucial for creating efficient therapies against mucormycosis in an era of growing immunocompromised patients and expanding infectious disease synergies.Keywords
This publication has 87 references indexed in Scilit:
- Epidemiological profile and clinical outcomes of patients with mucormycosis: the multicenter retromucor study from Türkiye (2004–2024)European Journal of Clinical Microbiology & Infectious Diseases, 2026
- Clinical and health economic impact of isavuconazole for treatment of invasive aspergillosis and mucormycosis: a retrospective, matched multicentre cohort study in GermanyInfection, 2025
- Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapyMedcomm, 2025
- Mucormycosis: a rare forgotten but fatal disease—a case report and literature reviewJournal of Rare Diseases, 2024
- Mucormycosis: A Rare disease to Notifiable DiseaseBrazilian Journal of Microbiology, 2024
- Fungal infections: Immune defense, immunotherapies and vaccinesAdvanced Drug Delivery Reviews, 2023
- Pathogenesis and Pathology of COVID-Associated Mucormycosis: What Is New and WhyCurrent Fungal Infection Reports, 2022
- Risks of mucormycosis in the current Covid-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patientsMolecular Biology Reports, 2022
- IFN-γ Mediated Signaling Improves Fungal Clearance in Experimental Pulmonary MucormycosisMycopathologia, 2021
- Host-Pathogen Molecular Factors Contribute to the Pathogenesis of Rhizopus spp. in Diabetes MellitusCurrent Tropical Medicine Reports, 2021